

IN THE CLAIMS:

1-3 (withdrawn)

4. (re-presented and amended) A polynucleotide encoding ~~the~~ a polypeptide according to ~~any one of the claims 1 to 3~~ selected from:

(a) a polypeptide comprising a CR-50 antibody recognition site of Reelin protein,  
and not containing an F-spondin domain or a repeat site, wherein the polypeptide is derived from  
a mouse Reelin polypeptide;

(b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO:2,  
and not containing an F-spondin domain or a repeat site; and

(c) the polypeptide of (a) or (b) comprising a deletion, substitution, or addition of  
one or more amino acid;

(d) a polypeptide encoded by a degenerative nucleic acid sequence of the  
polypeptides of any of (a) to (c); and

wherein the polypeptide binds to antibody CR-50.

5. (amended) A polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1 and  
not containing a nucleotide sequence encoding an F-spondin domain or a repeat domain, wherein  
the polypolynucleotide encodes a polypeptide that of binds a CR-50 antibody;

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

(b) a polynucleotide encoding a polypeptide capable of binding to a CR-50 antibody, ~~which wherein the polynucleotide~~ comprises deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence shown in SEQ ID NO: 1, and wherein the encoded polypeptide does not contain an F-spondin domain or a repeat site; and

(c) a polynucleotide comprising a degenerate nucleotide sequence of the polynucleotide polypeptide of (a) or (b).

6. (original) An expression vector comprising the polynucleotide according to claim 4 or 5.

7. (original) A host cell transfected with the expression vector according to claim 6.

8. (amended) A method for producing ~~the a polypeptide according to any one of claims 1 to 3~~, which comprises culturing the host cell according to claim 7.

9. (withdrawn)

10. (amended) A composition for stimulating the assembly of Reelin protein molecules, which comprises ~~the polypeptide according to any one of claims 1 to 3 or the polynucleotide~~ according to claim 4 or 5.

11. A pharmaceutical composition for diagnosis and/or treatment of diseases resulting from abnormally positioned neurons, which comprises ~~the polypeptide according to any one of claims 1 to 3 or the polynucleotide~~ according to claim 4 or 5.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com